Strijbos et al., 1993 - Google Patents
Impaired febrile responses of aging mice are mediated by endogenous lipocortin-1 (annexin-1)Strijbos et al., 1993
- Document ID
- 7538817566091597194
- Author
- Strijbos P
- Horan M
- Carey F
- Rothwell N
- Publication year
- Publication venue
- American Journal of Physiology-Endocrinology and Metabolism
External Links
Snippet
The mechanisms underlying age-related impairments in febrile responses were investigated in female C57Bl/lcrf-a (t) mice. Injection of norepinephrine, to assess total thermogenic capacity, significantly increased oxygen consumption (VO2) in all age groups, although the …
- 230000004044 response 0 title abstract description 109
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nauck et al. | Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. | |
| Kalff et al. | Role of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents | |
| Tsunekawa et al. | Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects | |
| Xu et al. | Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. | |
| DE68924372T2 (en) | TREATING DIABETES MELLITUS TYPE 2. | |
| Ellis et al. | Early life immune challenge alters innate immune responses to lipopolysaccharide: implications for host defense as adults | |
| Metz et al. | Induction of defective insulin secretion and impaired glucose tolerance by clonidine Selective stimulation of metabolic alpha-adrenergic pathways | |
| Waltman et al. | Spontaneous and glucocorticoid-inhibited adrenocorticotropic hormone and cortisol secretion are similar in healthy young and old men | |
| AU745241B2 (en) | Method for treating symptoms of diabetes | |
| Meininger et al. | Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution | |
| Williams et al. | Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours | |
| Strijbos et al. | Impaired febrile responses of aging mice are mediated by endogenous lipocortin-1 (annexin-1) | |
| HU206988B (en) | Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient | |
| SULLIVAN et al. | Hormonal regulation of immunoglobulins in the rat uterus: uterine response to multiple estradiol treatments | |
| BR112020006246A2 (en) | METHOD FOR WEIGHT CONTROL OF A SUBJECT IN NEED | |
| JPS60500174A (en) | Pharmaceutical preparations for treating peptic ulcers | |
| Jensen et al. | The identity of the glycotropic (anti-insulin) substance of the anterior pituitary gland | |
| Krassas et al. | Leptin levels in women with polycystic ovary syndrome before and after treatment with diazoxide | |
| Li et al. | Effect and mechanism of sodium butyrate on neuronal recovery and prognosis in diabetic stroke | |
| Foreman et al. | Nerve growth factor and p75NGFR factor receptor mRNA change in rodent CNS following stress activation of the hypothalamo‐pituitary‐adrenocortical axis | |
| Makkar et al. | Lrrc55 is a novel prosurvival factor in pancreatic islets | |
| Zha et al. | Serum factor (s) induced by restraint stress in mice and rats suppresses lymphocyte proliferation | |
| Cannavò et al. | Results of a two-year treatment with slow release lanreotide in acromegaly | |
| CA2194403A1 (en) | Use of igf-i or analogues thereof in the prevention of diabetes | |
| CN107050429B (en) | Application of human fibroblast growth factor 21 in the preparation of medicaments for the treatment of stroke |